Silvercrest Asset Management Group LLC Purchases 323,216 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Silvercrest Asset Management Group LLC increased its stake in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 77.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 742,914 shares of the company's stock after purchasing an additional 323,216 shares during the period. Silvercrest Asset Management Group LLC owned approximately 1.50% of Cryoport worth $5,780,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of CYRX. Point72 Asia Singapore Pte. Ltd. grew its stake in Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Cryoport during the 4th quarter worth approximately $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport during the 4th quarter worth approximately $64,000. Quarry LP acquired a new stake in shares of Cryoport during the 4th quarter worth approximately $69,000. Finally, ProShare Advisors LLC bought a new position in Cryoport in the fourth quarter valued at approximately $95,000. Institutional investors and hedge funds own 92.90% of the company's stock.

Cryoport Price Performance

CYRX stock traded down $0.20 during midday trading on Friday, reaching $6.02. 170,265 shares of the stock were exchanged, compared to its average volume of 542,845. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $11.64. The company has a fifty day moving average price of $5.94 and a 200 day moving average price of $6.84. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The stock has a market capitalization of $301.82 million, a PE ratio of -1.78 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The firm had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. As a group, analysts expect that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 19,830 shares of company stock worth $118,353 in the last ninety days. Company insiders own 10.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Guggenheim restated a "buy" rating and set a $10.00 target price on shares of Cryoport in a research note on Wednesday, April 16th. Morgan Stanley lowered their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Roth Mkm restated a "buy" rating and set a $15.00 price objective on shares of Cryoport in a research report on Tuesday, April 1st. UBS Group raised their price objective on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of Cryoport in a research note on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Cryoport has a consensus rating of "Moderate Buy" and an average price target of $11.00.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.